Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria
Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria
复制标题
DOI：
10.1007/bf01691117
复制
发表时间：
1998-03-01
影响因子：
4.5
通讯作者：
Nord, CE
中科院分区：
文献类型：
--
作者：
Edlund, C;Sabouri, S;Nord, CE
采用琼脂稀释法测定Bay12-8039对360株厌氧菌的体外抗菌活性，并与其他5种抗菌药物进行比较。BAY 12-8039和亚胺培南是测试中最活跃的药物。BAY 12-8039的MIC90值如下：消化链球菌(50株)，1 mg/L；痤疮丙酸杆菌(30株)，0.25 mg/L；边缘梭状芽孢杆菌(30株)，0.5 mg/L；艰难梭菌(50株)，2 mg/L；脆弱类杆菌(50株)，1 mg/L；非脆弱类杆菌，卟啉单胞菌和普氏杆菌。(10 0株)，2 mg/L；梭杆菌属。(50株)，0.25 mg/L。本研究结果表明，BAY12-8039可用于厌氧菌感染的治疗和预防。
The in vitro activity of BAY 12-8039 against 360 anaerobic clinical isolates was determined by the agar dilution method and compared to that of five other antimicrobial agents. BAY 12-8039 and imipenem were the most active agents tested. The following MIC90 values were determined for BAY 12-8039: Peptostreptococcus spp, (50 isolates), 1 mg/l; Propionibacterium acnes (30 isolates), 0.25 mg/l; Clostridium pel fringens (30 isolates), 0.5 mg/l; Clostridium difficile (50 isolates), 2 mg/l; Bacteroides fragilis (50 isolates), 1 mg/l; non-fragilis Bacteroides, Porphyromonas, and Prevotella spp. (100 isolates), 2 mg/l; and Fusobacterium spp. (50 isolates), 0.25 mg/l. The results of the present study show that BAY 12-8039 may be useful in the treatment and prophylaxis of anaerobic infections.